Company intelligence / Profile preview

Pleco Therapeutics

Nijmegen, Gelderland, Netherlandsplecotherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has announced a positive outcome from a pre-Investigational New Drug (pre‑IND) meeting with the FDA for its lead candidate PTX‑252 in Acute Myeloid Leukemia, indicating readiness to advance into clinical trials. Their approach aims to improve chemotherapy effectiveness by modulating protein expression and reducing toxic metals in cancer cells.

Therapeutic areas: Oncology
Modalities: Small molecules (Plecoid™ therapies)
Industry: Biotech

Drug pipeline

5 assets

PTX-142

Preclinical

4 more assets in the full pipeline.

Beyond the preview

Go deeper on Pleco Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pleco Therapeutics.